PYPL
62
2
EQR
40
-2
CCL
72
2
LEN
46
-3
RF
48
-3
LEG
36
5
WY
48
-2
PAYX
47
-3
PEP
41
-6
AVB
57
2
DHI
41
-4
A
41
-3
HAS
37
-4
TSN
32
-3
RIG
54
7
BAX
29
-4
NDAQ
56
4
MOS
50
4
XEL
53
-2
DRI
48
-2
PYPL
62
2
EQR
40
-2
CCL
72
2
LEN
46
-3
RF
48
-3
LEG
36
5
WY
48
-2
PAYX
47
-3
PEP
41
-6
AVB
57
2
DHI
41
-4
A
41
-3
HAS
37
-4
TSN
32
-3
RIG
54
7
BAX
29
-4
NDAQ
56
4
MOS
50
4
XEL
53
-2
DRI
48
-2
Financhill
Back

Reshape Lifesciences 10K Form

Sell
16

RSLS
Reshape Lifesciences

Last Price:
4.73
Seasonality Move:
-9%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive RSLS News And Ratings

See the #1 stock for the next 7 days that we like better than RSLS

RSLS Financial Statistics

Sales & Book Value

Annual Sales: $8.68M
Cash Flow: $-311K
Price / Cash Flow: 0
Annual Sales: $2.11
Price / Book: 2.42

Profitability

EPS (TTM): -16.00850
Net Income (TTM): $-7.07M
Gross Margin: $5.55M
Return on Equity: -187.93%
Return on Assets: -91.24%

Reshape Lifesciences Earnings Forecast

Key Reshape Lifesciences Financial Ratios

  • The Gross Profit Margin over the past 16 years for RSLS is 63.93%.
  • The Selling, General & Administrative Expenses for RSLS have been equal to 205.95% of Gross Profit Margin.
  • The Research & Development expenses have been 26.68% of Revenue.
  • The Interest Expense is -0.24% of Operating Income.
  • The Net Earning history of RSLS is -131.22% of Total Revenues.
  • Per Share Earnings over the last 21 years have been positive in 11 years.

Reshape Lifesciences Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Health Care Equipment & Supplies
Sector: Health Care
Current Symbol: RSLS
CUSIP: 761123
Website: reshapelifesciences.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 1.33
Quick Ratio: 0.52

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

RSLS Technical Analysis vs Fundamental Analysis

Sell
16
Reshape Lifesciences (RSLS) is a Sell

Is Reshape Lifesciences a Buy or a Sell?